Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zongertinib bioavailability study in fed vs fasted conditions
NCT06075277Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zongertinib (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 168 hours and Maximum Measured Concentration of the Zongertinib in Plasma at 168 hours. Started Oct 2023; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NCT06075277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075277.